Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan McCarthy, David Jayne, Bridget Griffiths et al.|Lara D. Veeken|2017Cited by 94
Differences in management approaches for lupus nephritis within the UKSara T. Ibrahim, John A. Reynolds, Christopher J Edwards et al.|Rheumatology Advances in Practice|2023Cited by 6
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan McCarthy, Emily Sutton, Stephanie Nesbit et al.|Lara D. Veeken|2017Cited by 4
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan McCarthy, Emily Sutton, Stephanie Nesbit et al.|Lara D. Veeken|2017Cited by 3